Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
16 Fevereiro 2022 - 6:05PM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces the
appointments of Samuel D. Riccitelli as Interim President and Chief
Executive Officer, succeeding Michael W. Nall, and Antonino Morales
as Interim Chief Financial Officer, succeeding Timothy C. Kennedy.
Biocept also named M. Faye Wilson as Lead Independent Director of
the company’s Board of Directors. Mr. Riccitelli remains Chair of
the Board.
“I am grateful and excited to see Sam and Antonino stepping into
their interim roles at a time when Biocept is fulfilling such an
important mission for our current COVID-19 testing clients and I am
even more excited about what their leadership will mean to
malignant tumor patients as we pursue the clinical validation of
the CNSide™ assay in identifying metastatic cancer originating from
all solid tumors,” said M. Faye Wilson, Lead Independent Director
of Biocept.
Mr. Riccitelli has served as a member of Biocept’s Board since
October 2020 and as Chair of the Board since June 2021. Mr.
Riccitelli has been in the healthcare industry for more than 35
years. He has served as a member of the Board of Directors of
Orthopediatrics, Inc. since 2017, a company focused exclusively on
the orthopedic implant needs of children. He recently served as
Chief Executive Officer of Pathnostics, LLC, a molecular
diagnostics company focused on improving antibiotic stewardship,
from 2019 to 2020. From 2017 to 2019, Mr. Riccitelli served as
Chair of the Board of Directors of Precipio, Inc., a diagnostic
services company. From 2012 to 2017, Mr. Riccitelli served as
President and Chief Executive Officer and a Director of Signal
Genetics, Inc., a publicly traded molecular diagnostic company that
was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli
was also previously the Executive Vice President and Chief
Operating Officer of Genoptix, Inc., a publicly traded diagnostic
company that was sold to Novartis in 2011. Mr. Riccitelli served in
a number of research and development and general management
leadership positions for Becton, Dickinson and Company and as a
vice president, general manager and board member for BD Ventures,
LLC., a venture capital fund.
Mr. Morales has served as a member of Biocept’s Board since July
2021 and as a member of Biocept’s Audit Committee from August 2021
until his appointment as Interim Chief Financial Officer. Mr.
Morales is a certified public accountant and has more than 30 years
of broad leadership experience in the US and Latin America. Mr.
Morales served as President and Chief Executive Officer of Apoyo
Financiero, Inc. from June 2017 to March 2020. Mr. Morales provides
operational, market development, and financial consulting services
for early stage companies in the United States as well as Fortune
500 companies in the United States and Latin America. He has served
in multiple senior management or consulting roles with various
Fortune 100 companies including Citibank, Bank of America, Arthur
Andersen, and Mazda North America.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although Biocept believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, Biocept can
give no assurance that such expectations and assumptions will prove
to have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "could,"
"expect," or "believe" or the negative of these words or other
variations on these words or comparable terminology. To the extent
that statements in this release are not strictly historical,
including without limitation statements regarding the effects of
the change in Biocept’s leadership, the capabilities and potential
benefits of Biocept’s CNSide assay and the ability of Biocept’s
assays to provide physicians with clinically actional information,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risks and uncertainties, including the risk that
Biocept’s products and services may not perform as expected. These
and other risks are described in greater detail under the "Risk
Factors" heading of Biocept’s Quarterly Report on Form 10-Q/A for
the quarter ended September 30, 2021, filed with the Securities and
Exchange Commission (SEC) on February 15, 2022. The effects of such
risks and uncertainties could cause Biocept’s actual results to
differ materially from the forward-looking statements contained in
this release. Biocept does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law. Readers are advised to review Biocept’s filings
with the SEC, which can be accessed over the Internet at the SEC's
website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220216006196/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024